Table 2 Plasmodium vivax recurrence in CQ alone and CQ + PQ treatment groups in Arjo-Didessa sugar development site and its surrounding, southwest Ethiopia (2019–2022)
Recurrences | CQ | CQ + PQ | p-value | ||
|---|---|---|---|---|---|
n | % | n | % | ||
Patients with no recurrence | 21 | 30.0 | 40 | 54.0 | 0.0035 |
Patients with recurrence: | 49 | 70.0 | 34 | 45.9 | |
 1 recurrence only | 14 | 28.6 | 11 | 33.3 | 0.8209 |
 2 recurrence | 12 | 24.5 | 10 | 30.3 | |
 3 recurrence | 15 | 30.6 | 8 | 24.2 | |
  > 4 recurrence | 8 | 16.3 | 4 | 12.1 | |
Time intervals from enrolment to first recurrence: | |||||
 29–180 days | 41 | 83.7 | 29 | 85.3 | 0.8417 |
  > 180 days | 8 | 16.3 | 5 | 14.7 | |
Number of recurrences/individual (Median [IQR]; max) | (2 [1–3]; 5) | (2 [1–3]; 8) |  | ||
Median time from enrolment to first recurrence (days), [IQR] | 60[29–146] | 95[29–149.2] |  | ||
All vivax malaria by diagnostic methods | |||||
 Microscopy and PCR | 89 | 74.2 | 47 | 61.0 |  |
 qPCR | 31 | 25.8 | 30 | 38.9 | 0.0518 |
All qPCR detected recurrence by symptom | |||||
 Symptomatic | 10 | 8.3 | 16 | 20.5 |  |
 Asymptomatic | 110 | 91.7 | 62 | 79.5 | 0.0218 |